{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"6.6","upperLimit":"13.0","value":"9.5"}]}],"title":"RECIST 1.1"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"6.6","upperLimit":"25.1","value":"18.4"}]}],"title":"mRECIST 1.1"}],"denoms":[{"counts":[{"groupId":"OG000","value":"28"}],"units":"Participants"}],"description":"From date of registration to Step 1 to date of first documentation of progression by RECIST 1.1 and modified RECIST 1.1, symptomatic deterioration, or death due to any cause. Participants last known to be alive and progression free are censored at date of last disease assessment.","dispersionType":"95% Confidence Interval","groups":[{"description":"NEOADJUVANT: Patients receive atezolizumab IV over 30-60 minutes, pemetrexed disodium IV over 10 minutes, and cisplatin IV over 2 hours on day 1. Cycles repeats every 21 days for 4 cycles in the absence of disease progression or unexpected toxicity.\n\nSURGERY: Within 21-90 days after completion of neoadjuvant therapy, patients undergo extrapleural pneumonectomy (EPP) or pleurectomy/decortication (PD). Patients who undergo EPP will then undergo radiation therapy.\n\nMAINTENANCE: Within 90 days after completion of either PD or radiation (post-EPP), patients receive atezolizumab IV over 60 minutes on day 1. Treatment repeats every 21 days for up to 1 year in the absence of disease progression or unexpected toxicity.","id":"OG000","title":"Treatment (Chemotherapy, Surgery +/- RT, Maintenance)"}],"paramType":"MEDIAN","populationDescription":"Eligible and evaluable participants.","reportingStatus":"POSTED","timeFrame":"Duration of treatment and follow-up until death or 3 years post Step 1 registration.","title":"Progression Free Survival (PFS)","type":"SECONDARY","unitOfMeasure":"Months"}